Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
15.88
+0.23 (1.47%)
Jan 27, 2026, 11:23 AM EST - Market open

Avalo Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
294787471914,212
Upgrade
Market Cap Growth
302.16%965.79%-84.63%-75.15%-95.47%-77.67%
Upgrade
Enterprise Value
179-1-1521534,180
Upgrade
Last Close Price
15.657.439.101209.614895.967603.14
Upgrade
PS Ratio
1508.98176.293.792.6335.37628.78
Upgrade
PB Ratio
3.050.581.00-4.358.27171.49
Upgrade
P/TBV Ratio
3.570.63--22.11491.62
Upgrade
EV/Sales Ratio
930.53--2.8728.36624.03
Upgrade
Debt / Equity Ratio
0.010.010.26-1.981.530.06
Upgrade
Asset Turnover
0.000.010.070.320.090.17
Upgrade
Inventory Turnover
---896.212444.832074.05
Upgrade
Quick Ratio
14.0019.421.640.682.991.53
Upgrade
Current Ratio
14.2819.951.820.743.111.71
Upgrade
Return on Equity (ROE)
-174.79%-50.06%--684.77%-354.08%-282.65%
Upgrade
Return on Assets (ROA)
-37.18%-29.75%-53.91%-32.95%-82.82%-74.02%
Upgrade
Return on Invested Capital (ROIC)
--6834.61%--4261.92%-1501.54%-367.18%
Upgrade
Return on Capital Employed (ROCE)
-56.80%-28.40%-143.20%-266.10%-136.20%-165.80%
Upgrade
Earnings Yield
-34.41%-45.18%-432.43%-87.80%-44.19%-1.51%
Upgrade
FCF Yield
-18.04%-63.10%-422.75%-56.58%-37.19%-0.96%
Upgrade
Buyback Yield / Dilution
-450.90%-2599.19%-608.45%-8.32%-41.86%-28.52%
Upgrade
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q